Shu-sen Yang
About
In The Last Decade
Shu-sen Yang
22 papers receiving 382 citations
Peers
Comparison fields: 5 of 68
- Cardiology and Cardiovascular Medicine 193
- Molecular Biology 154
- Cancer Research 52
- Radiology, Nuclear Medicine and Imaging 40
- Immunology 34
Countries citing papers authored by Shu-sen Yang
This map shows the geographic impact of Shu-sen Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shu-sen Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shu-sen Yang more than expected).
Fields of papers citing papers by Shu-sen Yang
This network shows the impact of papers produced by Shu-sen Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shu-sen Yang. The network helps show where Shu-sen Yang may publish in the future.
Co-authorship network of co-authors of Shu-sen Yang
This figure shows the co-authorship network connecting the top 25 collaborators of Shu-sen Yang. A scholar is included among the top collaborators of Shu-sen Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shu-sen Yang. Shu-sen Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 70 | |
| 3 | 29 | |
| 4 | 24 | |
| 5 | 28 | |
| 6 | 2 | |
| 7 | [The effect of carvedilol on coronary flow reserve in patients with dilated cardiomyopathy]. | 6 |
| 8 | [Atorvastatin use and coronary flow reserve in patients with coronary slow flow]. | 3 |
| 9 | Rapamycin protects heart from ischemia/reperfusion injury independent of autophagy by activating PI3 kinase-Akt pathway and mitochondria K(ATP) channel. | 23 |
| 10 | 9 | |
| 11 | 10 | |
| 12 | Effects of trimetazidine on atrial structural remodeling and platelet activation in dogs with atrial fibrillation. | 1 |
| 13 | Probucol attenuates atrial autonomic remodeling in a canine model of atrial fibrillation produced by prolonged atrial pacing. | 23 |
| 14 | 44 | |
| 15 | [Effects of autophagy in myocardial ischemia and ischemia/reperfusion injury]. | 1 |
| 16 | [Effects of chronic trimetazidine treatment on atrial energy metabolism in a canine model of chronic atrial fibrillation]. | 1 |
| 17 | [Chronic effects of percutaneous transmyocardial laser revascularization in patients with refractory angina]. | 3 |
| 18 | 40 | |
| 19 | [The experimental study on changes of endothelial nitric oxide synthase and plasminogen activator inhibitor-1 protein in the canine atrial fibrillation model]. | 4 |
| 20 | Effects of Losartan on acute atrial electrical remodeling. | 15 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.